𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine

✍ Scribed by Frithjof Tergau; Stephan Wischer; Christian Wolf; Walter Paulus

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
293 KB
Volume
16
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug‐free interval of 1 week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 ± 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS. © 2001 Movement Disorder Society.

📜 SIMILAR VOLUMES

Dopamine agonists restore cortical plast
Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome
✍ Vincenzo Rizzo; Irene Aricò; Claudia Mastroeni; Francesca Morgante; Giovanna Lio 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract In the present work, we aimed at assessing whether patients with idiopathic restless legs syndrome (RLS) showed alterations of sensory‐motor plasticity, an indirect probe for motor learning, within the motor cortex (M1). Previous findings suggest that learning in human M1 occurs through

Augmentation of restless legs syndrome w
Augmentation of restless legs syndrome with long-term tramadol treatment
✍ Roberto Vetrugno; Chiara La Morgia; Roberto D'Angelo; Daniela Loi; Federica Prov 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract Restless legs syndrome (RLS) augmentation, defined as a kind of suppression of the circadian rhythm of the disease in which sensory and motor symptoms appear earlier during the day (and over previously unaffected body parts), with a progressive phase advance until, backwards, the sympto

Treatment of restless leg syndrome with
Treatment of restless leg syndrome with pergolide—an open clinical trial
✍ Juliane Winkelmann; Thomas C. Wetter; Karen Stiasny; Wolfgang H. Oertel; Claudia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

## Abstract Dopaminergic treatment with levodopa (L‐dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end‐of‐dose rebound phenomena under L‐dopa/decarboxylase inhibitor treatment present major problems in some patients.

Patch application of the dopamine agonis
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double-blind, placebo-controlled pilot study
✍ Karin Stiasny-Kolster; Ralf Kohnen; Erwin Schollmayer; J. Carsten Möller; Wolfga 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 1 views

## Abstract Efficacy and safety of the dopamine agonist rotigotine (RTG) was investigated in patients with moderate to severe idiopathic restless legs syndrome (RLS), including daytime symptoms. Three fixed doses of rotigotine (1.125 mg, 2.25 mg, and 4.5 mg) and placebo were applied by patches (siz

One-year treatment with standard and sus
One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
✍ Claudia Trenkwalder; Victor Collado Seidel; Jörg Kazenwadel; Thomas C. Wetter; W 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract To investigate the long‐term efficacy and safety of sustained‐release (SR) in combination with regular‐release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open‐label, prospective, extension study of a preceding double‐blind crossover trial was performe